vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v21i2.2386vsp-2879Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLESЭффективность и безопасность иммунизации пептидной вакциной для профилактики инфекции, вызванной SARS-CoV-2: проспективное исследование среди медицинских работниковEfficacy and Safety of Peptide Vaccine in Prevention of SARS-CoV-2 Infection: Prospective Study among Healthcare Professionalshttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва; Белгород

Moscow; Belgorod

https://orcid.org/0000-0003-0797-5612ФедосеенкоМ. В.FedoseenkoMarina V.

кандидат медицинских наук, ведущий научный сотрудник отдела разработки научных подходов, к иммунизации пациентов с отклонениями в состоянии здоровья и хроническими болезнями НИИ педиатрии и охраны здоровья детей ЦКБ РАН

119333, Москва, ул. Фотиевой, д. 10, стр. 1, тел.: +7 (499) 137-01-97

Moscow

titovamarina@mail.ruhttps://orcid.org/0000-0002-3270-4374ШахтахтинскаяФ. Ч.ShakhtakhtinskayaFiruza Ch.

Москва

Moscow

https://orcid.org/0000-0003-1453-4671КалюжнаяТ. А.KaliuzhnaiaTatiana A.

Москва

Moscow

https://orcid.org/0000-0002-6150-0880СолошенкоМ. А.SoloshenkoMargarita A.

Москва

Moscow

https://orcid.org/0000-0001-5808-1438ТолстоваС. В.TolstovaSvetlana V.

Москва

Moscow

https://orcid.org/0000-0002-8590-4783СельвянА. М.SelvyanArevaluis M.

Москва

Moscow

ПриваловаТ. Е.PrivalovaTatiana E.

Москва

Moscow

https://orcid.org/0000-0002-3540-772XТимошковаС. Д.TimoshkovaSnezhana D.

Москва

Moscow

https://orcid.org/0000-0002-0279-9974МельниковаА. А.MelnikovaAlbina A.

Москва

Moscow

https://orcid.org/0000-0001-9257-0171ГореловА. В.GorelovAleksandr V.

Москва

Moscow

https://orcid.org/0000-0002-3612-1889ПлоскиреваА. А.PloskirevaAntonina A.

Москва

Moscow

https://orcid.org/0000-0002-3960-6830МустафинаИ. З.MustafinaIlina Z.

Москва

Moscow

https://orcid.org/0000-0002-9238-9302МелехинаЕ. В.MelekhinaElena V.

Москва

Moscow

https://orcid.org/0000-0001-5232-7337УсенкоД. В.UsenkoDenis V.

Москва

Moscow

https://orcid.org/0000-0002-6539-4878ПонежеваЖ. Б.PonezhevaZhanna B.

Москва

Moscow

https://orcid.org/0000-0002-9682-2230ОмароваХ. Г.OmarovaKhadizhat G.

Москва

Moscow

НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования Российской Федерации; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова; Белгородский государственный национальный исследовательский университетРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod National Research UniversityRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования Российской Федерации; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical UniversityRussian FederationНИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования Российской ФедерацииРоссияResearch Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationФедеральная служба по надзору в сфере защиты прав потребителей и благополучия человекаРоссияFederal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian FederationФБУН ЦНИИ эпидемиологии РоспотребнадзораРоссияCentral Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human WellbeingRussian Federation2022110420222128394Copyright © Намазова-Баранова Л.С., Федосеенко М.В., Шахтахтинская Ф.Ч., Калюжная Т.А., Солошенко М.А., Толстова С.В., Сельвян А.М., Привалова Т.Е., Тимошкова С.Д., Мельникова А.А., Горелов А.В., Плоскирева А.А., Мустафина И.З., Мелехина Е.В., Усенко Д.В., Понежева Ж.Б., Омарова Х.Г., 20222022Намазова-Баранова Л.С., Федосеенко М.В., Шахтахтинская Ф.Ч., Калюжная Т.А., Солошенко М.А., Толстова С.В., Сельвян А.М., Привалова Т.Е., Тимошкова С.Д., Мельникова А.А., Горелов А.В., Плоскирева А.А., Мустафина И.З., Мелехина Е.В., Усенко Д.В., Понежева Ж.Б., Омарова Х.Г.Namazova-Baranova L.S., Fedoseenko M.V., Shakhtakhtinskaya F.C., Kaliuzhnaia T.A., Soloshenko M.A., Tolstova S.V., Selvyan A.M., Privalova T.E., Timoshkova S.D., Melnikova A.A., Gorelov A.V., Ploskireva A.A., Mustafina I.Z., Melekhina E.V., Usenko D.V., Ponezheva Z.B., Omarova K.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2879

Пандемия, вызванная новой коронавирусной инфекцией, по-прежнему является одной из ключевых проблем здравоохранения и представляет серьезную угрозу для всей планеты. В настоящее время в Российской Федерации, как и во всех странах, продолжается активная иммунизация против коронавирусной инфекции нового типа. Вакцинация является важнейшей компонентой в комплексной программе профилактики заболевания COVID-19 и контроля над данной инфекцией. Массовая иммунизация населения способна предотвратить как обращения за медицинской помощью, так и госпитализации в условиях высокой заболеваемости COVID-19 и, тем самым, снизить нагрузку на систему здравоохранения. Несмотря на сохраняющиеся сложности в борьбе с пандемией, вызванной SARS-CоV-2, на сегодняшний день вакцинопрофилактика является самым действенным методом защиты от данной инфекции. В условиях экстренного разрешения использования вакцин против новой коронавирусной инфекции, меняющейся эпидемиологической ситуации и широкой вариабельности разных типов применяемых вакцин клинические исследования эффективности различных профилактических прививок в разных регионах мира чрезвычайно актуальны. По мере развития пандемии всем странам потребуются постоянно обновляющиеся данные об эффективности вакцин для решения новых проблем, таких как ослабление поствакцинальной защиты, появление новых штаммов вируса SARS-CoV-2 и необходимость использования других профилактических мер по смягчению действия пандемии.

The pandemic caused by the new coronavirus infection remains the topical health issue and constitutes serious threat to the entire world. Nowadays, active immunization against new type of coronavirus infection continues in Russian Federation and in all other countries. Vaccination is the crucial component in comprehensive program for COVID-19 prevention and control. Mass immunization of population can prevent both admissions and hospitalization in conditions of high incidence of COVID-19 and thereby reduce the burden on the health system. Despite the remaining complications in combating the SARS-CoV-2 pandemic, preventive vaccination is by far the most effective method for protection against this infection Clinical studies on the efficacy of various preventive vaccinations in different regions of the world are extremely relevant especially under conditions of the emergency use authorization for vaccines against new coronavirus infection, the changing epidemiological situation, and the wide variability of different types of vaccines. All countries will need continuously updated data on vaccine efficacy to address new challenges such as weakening post-vaccine protection, new SARS-CoV-2 strains, and need for other preventive measures to mitigate the pandemic.

коронавирусная инфекцияCOVID-19вакцинацияпептидная вакцинапрофилактикаcoronavirus diseaseCOVID-19vaccinationpeptide vaccinepreventionНе указан.Not specified.ReferencesCOVID-19 Coronavirus Pandemic. In: Worldometer. Available online: https://www.worldometers.info/coronavirus/#countries. Accessed on January, 19, 2022.COVID-19 Coronavirus Pandemic. In: Worldometer. Available online: https://www.worldometers.info/coronavirus/#countries. Accessed on January, 19, 2022.Информация о случаях заболевания COVID-19 в России и мире // Роспотребнадзор. Доступно по: https://www.rospotrebnadzor.ru/region/korono_virus/epid.php. Ссылка активна на 27.02.2022.Information on cases of COVID-19 in Russia and the world. In: Rospotrebnadzor. (In Russ). Доступно по: https://www.rospotrebnadzor.ru/region/korono_virus/epid.php. Ссылка активна на 27.02.2022.Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage В beta-coronaviruses. Nat Microbiol. 2020;5(4):562–569. doi: https://doi.org/10.1038/s41564-020-0688-yLetko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage В beta-coronaviruses. Nat Microbiol. 2020;5(4):562–569. doi: https://doi.org/10.1038/s41564-020-0688-yModerbacher CR, Ramirez SI, Dan JM, et al. Antigenspecific adaptive immunity to SARSCoV2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19. doi: https://doi.org/10.1016/j.cell.2020.09.038Moderbacher CR, Ramirez SI, Dan JM, et al. Antigenspecific adaptive immunity to SARSCoV2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19. doi: https://doi.org/10.1016/j.cell.2020.09.038COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600(7889):472–477. doi: https://doi.org/10.1038/s41586-021-03767-xCOVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021;600(7889):472–477. doi: https://doi.org/10.1038/s41586-021-03767-xJin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi: https://doi.org/10.3389/fpubh.2020.00152Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. doi: https://doi.org/10.3389/fpubh.2020.00152Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: https://doi.org/10.1136/bmj.m1985Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi: https://doi.org/10.1136/bmj.m1985Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death in 17 million patients. Nature. 2020;584(7821):430–436. doi: https://doi.org/10.1038/s41586-020-2521-4Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death in 17 million patients. Nature. 2020;584(7821):430–436. doi: https://doi.org/10.1038/s41586- 020-2521-4Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36:e3319. doi: https://doi.org/10.1002/dmrr.3319Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36:e3319. doi: https://doi.org/10.1002/dmrr.3319Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020;36:e3321. doi: https://doi.org/10.1002/dmrr.3321Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020;36:e3321. doi: https://doi.org/10.1002/dmrr.3321Vaccine Market Dashboard. In: UNICEF. Available online: https://www.unicef.org/supply/covid-19-vaccine-marketdashboard. Accessed on January 19, 2022.Vaccine Market Dashboard. In: UNICEF. Available online: https://www.unicef.org/supply/covid-19-vaccine-marketdashboard. Accessed on January 19, 2022.ВОЗ. Рекомендации ВОЗ для населения в связи c распространением нового коронавируса (2019-nCoV): мифы и ложные представления // Всемирная организация здравоохранения. — 19 января 2022. Доступно по: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters. Ссылка активна на 27.02.2022.WHO. Coronavirus disease (COVID-19) advice for the public: Mythbusters. In: World Health Organization. 19 January 2022. (In Russ). Доступно по: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters. Ссылка активна на 27.02.2022.Совещание Европейской технической консультативной группы экспертов по иммунизации: виртуальное совещание 11–12 ноября 2020 г. — Копенгаген: Европейское региональное бюро ВОЗ; 2021. Доступно по: https://apps.who.int/iris/bitstream/handle/10665/341394/WHO-EURO-2021-1808-41559-57119-rus.pdf. Ссылка активна на 27.02.2022.20th meeting of the European Technical Advisory Group of Experts on Immunization: virtual meeting 11–12 November 2020. Copenhagen: WHO Regional Office for Europe; 2021. (In Russ).Доступно по: https://apps.who.int/iris/bitstream/handle/10665/341394/WHO-EURO-2021-1808-41559-57119-rus.pdf. Ссылка активна на 27.02.2022.ВОЗ. Оценка эффективности вакцины против COVID-19: временное руководство, 17 марта 2021. — Женева: Всемирная организация здравоохранения; 2021. Доступно по: https://apps.who.int/iris/bitstream/handle/10665/340301/ WHO-2019-nCoV-vaccine-effectiveness-measurement-2021.1-rus.pdf. Ссылка активна на 27.02.2021.WHO. Evaluation of COVID-19 vaccine effectiveness: Interim Guidance, 17 Marth 2021. Geneva: World Health Organization; 2021. (In Russ).Доступно по: https://apps.who.int/iris/bitstream/handle/10665/340301/WHO-2019-nCoV-vaccine-effectiveness-measurement-2021.1-rus.pdf. Ссылка активна на 27.02.2021.Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of COVID-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244. doi: https://doi.org/10.1136/bmj.n2244Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of COVID-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244. doi: https://doi.org/10.1136/bmj.n2244Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П. и др. Простое слепое плацебо-контролируемое рандомизированное исследование безопасности, реактогенности и иммуногенности вакцины «ЭпиВакКорона» для профилактики COVID-19 на добровольцах в возрасте 18–60 лет (фаза I–II) // Инфекция и иммунитет. — 2021. — Т. 11. — № 2. — С. 283–296. — doi: https://doi.org/10.15789/2220-7619-ASB-1699Ryzhikov AB, Ryzhikov ЕА, Bogryantseva MP, et al. A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II). Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2021;11(2): 283–296. (In Russ). doi: https://doi.org/10.15789/2220-7619-ASB-1699Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П. и др. Имму ногенные и протективые свойства пептидной вакцины против SARS-CoV-2 // Вестник РАМН. — 2021. — Т. 76. — № 1. — С. 5–19. — doi: https://doi.org/10.15690/vramn1528Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, et al. Immunogenicity and Protectivity of the Peptide Vaccine against SARS-CoV-2. Annals of the Russian Academy of Medical Sciences. 2021;76(1):5–19. (In Russ). doi: https://doi.org/10.15690/vramn1528Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539–48. doi: https://doi.org/10.1016/S1473-3099(21)00330-3Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539–48. doi: https://doi.org/10.1016/S1473-3099(21)00330-3Barnabas RV, Wald A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann Intern Med. 2021;174(4):552–553. doi: https://doi.org/10.7326/M20-8060Barnabas RV, Wald A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann Intern Med. 2021;174(4):552–553. doi: https://doi.org/10.7326/M20-8060Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. doi: https://doi.org/10.1016/S0140-6736(21)00947-8Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. doi: https://doi.org/10.1016/S0140-6736(21)00947-8Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275): 671–681. doi: https://doi.org/10.1016/S0140-6736(21)00234-8Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275): 671–681. doi: https://doi.org/10.1016/S0140-6736(21)00234-8COVID-19 vaccine surveillance report. Week 42. UK Health Security Agency; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-reportweek-42.pdf. Accessed on February 27, 2022.COVID-19 vaccine surveillance report. Week 42. UK Health Security Agency; 2021. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1027511/Vaccine-surveillance-reportweek-42.pdf. Accessed on February 27, 2022.Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8:100158. doi: https://doi.org/10.1016/j.lanepe.2021.100158Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8:100158. doi: https://doi.org/10.1016/j.lanepe.2021.100158Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):631. doi: https://doi.org/10.1038/s41467-020-19741-6Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):631. doi: https://doi.org/10.1038/s41467-020-19741-6Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–793. doi: https://doi.org/10.1001/jama.2020.12839Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–793. doi: https://doi.org/10.1001/jama.2020.12839Wall ЕC, Wu М, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-2333. doi: https://doi.org/10.1016/S0140-6736(21)01290-3Wall ЕC, Wu М, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-2333. doi: https://doi.org/10.1016/S0140-6736(21)01290-3Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi: https://doi.org/10.1001/jamainternmed.2020.0994Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943. doi: https://doi.org/10.1001/jamainternmed.2020.0994Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi: https://doi.org/10.1111/jth.14768Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi: https://doi.org/10.1111/jth.14768Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi: https://doi.org/10.1016/S2352-3026(20)30145-9Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi: https://doi.org/10.1016/S2352-3026(20)30145-9Костинов М.П., Хромова Е.А., Костинова А.М. Может ли вакцинация против гриппа быть неспецифической профилактикой SARS-COV-2 и других респираторных инфекций? // Инфекционные болезни: новости, мнения, обучение. — 2020. — Т. 9. — № 3. — С. 36–40. — doi: https://doi.org/10.33029/2305-3496-2020-9-3-36-40Kostinov M.P., Khromova E.A., Kostinova A.M. Could influenza vaccination be a non-specific prevention of SARS-CoV-2 and other respiratory infections? Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2020;9(3):36–40. (In Russ). doi: https://doi.org/10.33029/2305-3496-2020-9-3-36-40Voysey M, Clemens SAC, Madh SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111 doi: https://doi.org/10.1016/S0140-6736(20)32661-1Voysey M, Clemens SAC, Madh SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111 doi: https://doi.org/10.1016/S0140-6736(20)32661-1Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383: 2603–2615. doi: https://doi.org/10.1056/NEJMoa2034577Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383: 2603–2615. doi: https://doi.org/10.1056/NEJMoa2034577

The authors declare that there are no conflicts of interest present.